- Home
- Publications
- Publication Search
- Publication Details
Title
Bone-targeting agents in prostate cancer
Authors
Keywords
Bone-targeting agents, Prostate cancer, Bone metastases
Journal
CANCER AND METASTASIS REVIEWS
Volume 33, Issue 2-3, Pages 619-628
Publisher
Springer Nature
Online
2014-01-07
DOI
10.1007/s10555-013-9480-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche
- (2015) Yusuke Shiozawa et al. NEOPLASIA
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
- (2013) John C Araujo et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation
- (2013) Russell S. Taichman et al. PLoS One
- Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
- (2013) K Miller et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Novel and bone-targeted agents for CRPC
- (2012) K. Fizazi et al. ANNALS OF ONCOLOGY
- The prostate cancer bone marrow niche: more than just ‘fertile soil’
- (2012) Elisabeth A Pedersen et al. ASIAN JOURNAL OF ANDROLOGY
- Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
- (2012) Joel B. Nelson et al. CANCER
- Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
- (2012) J. T. Isaacs et al. CANCER RESEARCH
- Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
- (2012) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
- (2012) S. Nilsson et al. EUROPEAN JOURNAL OF CANCER
- Hepatocyte growth factor-induced BMP-2 expression is mediated by c-Met receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts
- (2012) Shu-Yao Tsai et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib combined with docetaxel for castration-resistant prostate cancer
- (2011) John C. Araujo et al. CANCER
- Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow
- (2011) Yusuke Shiozawa et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- (2011) Roberto Pili et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)
- (2011) Karin Jennbacken et al. PROSTATE
- Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
- (2010) Nicholas D. James et al. BJU INTERNATIONAL
- The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial
- (2010) Anders Bonde Jensen et al. Clinical Breast Cancer
- Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer
- (2010) Joanne Edwards EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer
- (2010) John T Isaacs EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
- (2010) Anders Olsson et al. Molecular Cancer
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
- (2010) Y-C Lee et al. ONCOGENE
- Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells
- (2009) Eric Sulpice et al. BIOLOGY OF THE CELL
- Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
- (2009) O Bratt et al. BRITISH JOURNAL OF CANCER
- Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
- (2009) O. Tatarov et al. CLINICAL CANCER RESEARCH
- A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
- (2009) William R. Schelman et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- ZOLEDRONIC ACID FOR THE PREVENTION OF BONE METASTASES IN HIGH RISK PROSTATE CANCER PATIENTS. A RANDOMISED, OPEN LABEL, MULTICENTRE STUDY OF THE EUROPEAN ASSOCIATION OF UROLOGY (EAU) IN COOPERATION WITH THE SCANDINAVIAN PROSTATE CANCER GROUP (SPCG) AND THE ARBEITSGEMEINSCHAFT UROLOGISCHE ONKOLOGIE (AUO)
- (2008) M. Wirth et al. EUROPEAN UROLOGY SUPPLEMENTS
- Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor
- (2008) N Brownlow et al. LEUKEMIA
- Thalidomide and lenalidomide: Mechanism-based potential drug combinations
- (2008) Sonia Vallet et al. LEUKEMIA & LYMPHOMA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now